Victory Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Victory Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.69M	Buy	81,941 +312	+0.4%	+$6.66K	﹤0.01%	1713
2026 Q2	$1.5M	Sell	81,629 -106,548	-57%	-$1.72M	﹤0.01%	1720
2026 Q1	$3.68M	Sell	188,177 -38,640	-17%	-$1.15M	﹤0.01%	1425
2025 Q4	$7.06M	Sell	226,817 -205,603	-48%	-$5.64M	﹤0.01%	1171
2025 Q3	$9.33M	Sell	432,420 -132,370	-23%	-$2.39M	0.01%	1128
2025 Q2	$7.9M	Buy	564,790 +11,940	+2%	+$162K	0.01%	1179
2025 Q1	$7.45M	Buy	552,850 +142,410	+35%	+$2.43M	0.01%	1156
2024 Q4	$7.87M	Buy	+410,440	New	+$8.92M	0.01%	1150
2020 Q2	–	Sell	-512	Closed	-$3K	–	3280
2020 Q1	$3K	Buy	+512	New	+$5.96K	﹤0.01%	3428
2019 Q4	–	Sell	-264	Closed	-$3K	–	3275
2019 Q3	$3K	Buy	+264	New	+$5.84K	﹤0.01%	3580

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Victory Capital Management's VRDN Position: Q3 2026 in Review

Victory Capital Management increased its Viridian Therapeutics (VRDN) stake by 0.38% in Q3 2026, buying an estimated $6.66K and bringing the position to 81,941 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #1713.

Victory Capital Management first reported a position in VRDN in Q3 2019 and has held it in 10 quarters since. The position peaked at $9.33M in Q3 2025. 154 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

Victory Capital Management held 81,941 shares of Viridian Therapeutics worth $1.69M as of Q3 2026.
Victory Capital Management bought 312 Viridian Therapeutics shares in Q3 2026, an estimated $6.66K.
Viridian Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q3 2026, its #1713 holding.
Victory Capital Management first reported a position in Viridian Therapeutics in Q3 2019 and has held it in 10 quarters since.
Victory Capital Management's Viridian Therapeutics position peaked at $9.33M in Q3 2025.
154 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Victory Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.